Last $97.96 USD
Change Today +1.05 / 1.08%
Volume 1.1M
MDVN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

medivation inc (MDVN) Snapshot

Open
$97.02
Previous Close
$96.91
Day High
$98.42
Day Low
$96.05
52 Week High
09/17/14 - $98.42
52 Week Low
10/22/13 - $48.15
Market Cap
7.5B
Average Volume 10 Days
1.5M
EPS TTM
$0.27
Shares Outstanding
76.8M
EX-Date
07/27/99
P/E TM
362.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDIVATION INC (MDVN)

medivation inc (MDVN) Related Businessweek News

No Related Businessweek News Found

medivation inc (MDVN) Details

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company also conducts various trials of enzalutamide in earlier prostate cancer disease states, including the Phase III PREVAIL trial in patients with mCRPC who have not received chemotherapy; and in patients with breast cancer. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI. The company is headquartered in San Francisco, California.

433 Employees
Last Reported Date: 08/7/14

medivation inc (MDVN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $750.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $480.4K
Chief Compliance Officer, General Counsel and...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

medivation inc (MDVN) Key Developments

Astellas Pharma Inc. and Medivation, Inc. Announce U.S. Food and Drug Administration Approval for the Use of XTANDI (Enzalutamide) Capsules

Astellas Pharma Inc. and Medivation, Inc. announced that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved use follows a priority review of the supplemental New Drug Application (sNDA) that was based on results of the Phase 3 PREVAIL trial. The FDA initially approved XTANDI, an oral, once-daily androgen receptor inhibitor for use in patients with metastatic CRPC who previously received docetaxel (chemotherapy). The new indication approves XTANDI for use in men with metastatic CRPC who have not received chemotherapy. In the Phase 3 PREVAIL trial, men receiving XTANDI and GnRH therapy exhibited a statistically significant improvement in both overall survival and delayed time to radiographic progression or death as compared to those on placebo and GnRH therapy. XTANDI significantly reduced the risk of death by 29% compared with placebo (HR=0.71; p < 0.0001). XTANDI significantly reduced the risk of radiographic progression or death by 83% compared with placebo (HR=0.17; p < 0.0001).

Medivation, Inc. - Special Call

Medivation, Inc. - Special Call

Medivation, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014

Medivation, Inc. Presents at Citi's 9th Annual Biotech Conference, Sep-03-2014 . Venue: The Mandarin Oriental Boston, 776 Boylston Street, Boston, MA 02119, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDVN:US $97.96 USD +1.05

MDVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Insys Therapeutics Inc $33.96 USD +0.55
InterMune Inc $73.74 USD 0.00
Pfizer Ltd/India 1,688 INR +14.35
Sanofi India Ltd 2,997 INR +42.90
Seattle Genetics Inc $41.38 USD -0.13
View Industry Companies
 

Industry Analysis

MDVN

Industry Average

Valuation MDVN Industry Range
Price/Earnings 100.0x
Price/Sales 18.9x
Price/Book 51.9x
Price/Cash Flow 313.9x
TEV/Sales 17.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIVATION INC, please visit www.medivation.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.